Therapeutic Goods (Medical Devices) Regulations 2002: Parts and Schedules

1. Key takeaways

The Therapeutic Goods (Medical Devices) Regulations 2002 is the primary operating manual for device compliance in Australia: eleven Parts govern processes and obligations, and the Schedules govern substantive requirements. To determine classification, consult Schedule 2 or 2A; to determine the floor of safety and performance, consult Schedule 1; to determine which conformity assessment route applies, consult Schedule 3; and to determine what fees must be paid, consult Schedule 5. Locating a question in the right Part or Schedule before drafting saves significant effort, because the instrument deliberately separates procedural machinery from substantive criteria, and the two are amended on different rhythms and for different policy reasons. Teams that treat the Regulations as one undifferentiated text tend to misread transitional provisions and to overlook fee items until they surface late in a project budget. The separation also explains why amendments appear unevenly: a procedural Part can be rewritten without any substantive criterion moving, while a Schedule can change the evidentiary floor for an entire product family in a single compilation. Reading the two dimensions separately is therefore the correct mental model, not merely a convenient one.

2. Legal basis

1. Therapeutic Goods (Medical Devices) Regulations 2002; registration number F2002B00237, series number SR 2002 No. 236; as made on 3 October 2002; current compilation F2026C00883 (C72), registered on 11 September 2026, effective on 8 September 2026; 70 versions in the compilation history.
2. Part structure of the body text: Part 1 preliminary; Part 2 Essential Principles; Part 3 conformity assessment (Div 3.1 classification, rr 3.1–3.3; Div 3.2 conformity assessment, rr 3.4–3.13); Part 4 conformity assessment certificates; Part 4A Australian conformance assessment bodies; Part 5 inclusion in the Register; Part 6 suspension and cancellation; Part 6A emergency handling of devices; Part 7 exemption from registration; Part 8 information; Part 8AA mandatory adverse event reporting by healthcare facilities; Part 8A fee reductions; Part 9 fees; Part 9A Australian UDI database; Part 10 miscellaneous; Part 11 transitional.
3. Schedule structure: Schedule 1 Essential Principles; Schedule 2 classification rules for non-IVD devices; Schedule 2A classification rules for IVDs; Schedule 3 conformity assessment procedures (including Parts 6A and 6B for in-house IVDs); Schedule 3AA requirements for Australian conformance assessment bodies; Schedule 3A emergency handling of devices; Schedule 4 exempt devices; Schedule 5 fees.
4. Sunset of the exemption for this instrument: item 63AA of section 12 of the Legislation (Exemptions and Other Matters) Regulation 2015.

3. Expert insights

Insight 1: Part 8AA and Part 9A are recently added organs of the instrument. Part 8AA carries mandatory adverse event reporting by healthcare facilities, and Part 9A carries the Australian UDI database (AusUDID). The arrival of these two Parts signals that the Regulations have expanded from pre-market control to whole-lifecycle data control, and the centre of gravity of compliance workload has shifted accordingly. Companies that still organise their compliance function purely around registration activities will find that the operational demands now sit increasingly in post-market data management, which requires different skills, different systems, and a different internal ownership structure than the original submission work.

Insight 2: Schedule 4 is often misread as an exemption from compliance altogether. Exemption only removes the obligation of inclusion in the ARTG; an exempt device may still carry advertising, adverse event reporting, and notification obligations. Exclusion, implemented through a Declaration under section 41BD(3) of the Act, is what means the article is not a medical device at all, and the legal consequences of the two mechanisms differ (see article 08 for details). Conflating them leads to quiet non-compliance: a company that believes it has no obligations stops reporting, while its product remains fully within the device regulatory perimeter.

Insight 3: The transitional provisions in Part 11 decide the fate of legacy products. When classification rules or software rules change, the transitional provisions in Part 11 define the window during which legacy products remain governed by the old rules. Reading new rules without reading Part 11 produces the erroneous conclusion that products already on sale are immediately non-compliant. Conversely, assuming an indefinite grace period is equally dangerous; the transition windows are finite and dated, and the only safe practice is to identify the applicable transition clause for each affected product at the moment a rule change is announced.

4. Practical recommendations

1. Build an internal index on the principle that Parts govern process and Schedules govern substance, mapping frequently used provisions to specific business actions so that non-regulatory colleagues can navigate the instrument without interpretive support. Reviewing the index whenever a compilation lands keeps it aligned with the live text rather than with the version people remember.
2. For products already on sale, perform an additional comparison against the Part 11 transitional provisions to confirm the date from which new rules apply to each product, and record that date in the product compliance file.
3. Build a cross-reference table pairing Schedule 4 (exemptions) with Schedule 5 (fees) and feed it into project cost estimates at initiation, so that exemption-related work is budgeted rather than discovered.
4. After each compilation update, prioritise comparison of Part 8AA, Part 9A, Schedule 1, and Schedule 3, because these four locations have concentrated the most changes in recent years and are the most likely to affect active product files. A short written summary of what changed, filed alongside the comparison, turns each update into an audit-ready record rather than an undocumented editing session.

5. Verification checklist

• □ The registration number F2002B00237 and the current compilation F2026C00883 (C72) have been recorded
• □ The division of labour among the eleven Parts and the eight Schedules is understood
• □ The Part 11 transitional provisions have been compared for the applicable start dates affecting marketed products
• □ The legal consequences of exemption and of exclusion have been distinguished
• □ Schedule 5 fee items have been incorporated into the cost model

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages TGA inclusion and ARTG listing applications, coordinates conformity assessment evidence, and supports post-market vigilance obligations. Business enquiries: info@grzan.cn